AU2013361865A1

AU2013361865A1 - Improved protection against body odor

Info

Publication number: AU2013361865A1
Application number: AU2013361865A
Authority: AU
Inventors: Annabell Aldag; Sina Brinkmann; Anette Burger; Marita Hallmann; Stefanie Kaninck; Ilka Oelrichs; Annika Scholz; Bernd Traupe; Michael Urban
Original assignee: Beiersdorf AG
Current assignee: Beiersdorf AG
Priority date: 2012-12-18
Filing date: 2013-12-04
Publication date: 2015-04-30
Anticipated expiration: 2033-12-04
Also published as: EP2934459B1; WO2014095366A3; WO2014095366A2; BR112015014109A2; BR112015014109B1; AU2013361865B2; DE102012223532A1; EP2934459A2

Abstract

Disclosed is a cosmetic or dermatological preparation which comprises zinc carboxylates and antimicrobial and/or antiperspirant compounds and which have a synergistically increased deodorant effect.

Description

1 Improved Protection Against Body Odor The invention is a cosmetic or dermatological preparation comprising zinc carboxylates and antimicrobial and/or antiperspirant compounds that exhibit increased deodorizing effectiveness. 5 Sweat refers to an aqueous secretion secreted from a human's skin by means of so-termed sweat glands. Body odor arises when the fresh sweat, which in itself is odorless, is decomposed by microorganisms, e.g., staphylococci and corynebacteria. Cosmetic antiperspirants or deodorants are used to eliminate body odor or to prevent body odor from arising. 10 The effectiveness of an antiperspirant preparations consists of the sweat-regulating effect and the prevention of sweat odor or body odor. Aluminum salts are usually used as antiperspirant active ingredients in such systems. Although aluminum salts have deodorizing properties in addition to the primary sweat regulating effect, there is a constant demand for improved effectiveness particularly with 15 regard to the antimicrobial or deodorizing action. EP 1541122 Al discloses deodorizing cosmetic preparations that comprise zinc pidolate and aluminum chlorohydrate in activated or non-activated form as an antiperspirant aluminum salt. Also disclosed is the use of the combination of zinc pidolate and aluminum chlorohydrate in 20 activated or non-activated from as a deodorizing active ingredient in a cosmetic composition. Zinc salts are known as odor-reducing agents, as deodorizing, as described, for example, in US 4425321. EP 768080 Al discloses deodorizing compositions comprising water-soluble zinc salts as odor absorbers, in particular zinc pidolate, zinc sulfate, zinc chloride, zinc lactate, zinc 25 gluconate. WO 2006074359 A2 describes the use of zinc salts in combination with other antimicrobial substances such as erythromycin. US 5662937 discloses deodorant preparations comprising talc, zinc oxide, and citric acid that are effective for long periods. 30 WO 2007076125 A2 describes antimicrobial preparations that contain a zinc compound, such as zinc acetate, zinc butyrate, zinc chloride, zinc citrate, zinc gluconate, zinc glycerate, zinc formate, and others. DE 102005032239 Al describes zinc stearate as a separating agent in a powder base.

2 DE 102008053034 Al describes the use of hydroxycinnamic acids and plant extracts as deodorizing active ingredients. Generally astringent salts of aluminum, zirconium, zinc, or titanium are disclosed as antiperspirant active ingredients. Combinations of aluminum chlorohydrate (ACH (20%)) with zinc gluconate, zinc pyrrolidone carboxylic acid, zinc cocoyl 5 ether sulfate, zinc glycinate monohydrate, or zinc lactate are described in various examples. DE 102010055816 Al discloses the combination of ACH (20%) and zinc lactate (0.2%) in deodorant/antiperspirant sprays. DE 60213209 T2 discloses pantothenate salts in water-free antiperspirant preparations, wherein the pantothenate salt can also be formed with zinc. The pantothenate salts should 10 be the more ACH-stable alternative to panthenol. DE 602004009495 T2 describes zinc salicylate in alcoholic deodorant sprays. DE 602005000901 T2 describes preparations for stabilizing W/O emulsions that contain at least one deodorizing salt. All known antiperspirant or deodorant active ingredients can be selected as a deodorizing salt. 15 US 6426061 B1 describes topical preparations for avoiding sweat odor that relatively specifically address mechanisms of odor production and use inhibitors of the expression of the androgen receptor, such as resveratrol, epigallocatechin-3-gallate, and flufenamic acid. The preparations necessarily comprise the aforementioned inhibitor (a) and additionally (b) an active ingredient for inhibiting carrier proteins, such as monensin, tunicamycin, 20 amphomycin, diumycin, showdomycin, tsushimycin, amphotericin, mycospocidin, streptovirudin, and/or D-glucosamine, (c) zinc salts as anti-DHT (dihydrotestosterone) active ingredients, (d) an Al-based antiperspirant active ingredient, and (e) an additional antimicrobial active ingredient, such as chlorhexidine digluconate and chlorhexidine diacetate. 25 US 7332154 B2 discloses a combination of zinc gluconate and an Al-based antiperspirant active ingredient. EP 1902754 Al discloses combinations of water-soluble zinc salts and salicylic acid in deodorant preparations. Zinc PCA, zinc sulfate, zinc chloride, zinc lactate, zinc gluconate, zinc phenolsulfonate, and zinc salicylate are listed as water-soluble zinc salts and are 30 described in combination with Al salts in a further embodiment. WO 2001089452 A2 describes antiperspirant-containing W/O emulsions having a low water content, in which a water-soluble, such as common salt, and also zinc citrate and/or zinc glycinate are named as optional. The addition is used to stabilize W/O emulsions by means of electrolytes.

3 It is desirable to provide antiperspirant preparations which, in addition to the antiperspirant effect, offer improved product performance with regard to the deodorant effect and the protection against body odor. In particular, it is desirable to provide preparations whose content of antiperspirant 5 compounds can be reduced without having to fear a decrease in effectiveness. It is also desirable to provide preparations that have a longer deodorizing effect than preparations known from the prior art without a decrease in skin compatibility. The invention is a cosmetic or dermatological preparation comprising one or more zinc salts of carboxylic acids (zinc carboxylates) and one or more antimicrobial and/or antiperspirant 10 compounds that are different from the zinc salts. The combination of one or more zinc salt of the carboxylic acids (zinc carboxylates) with one or more antiperspirant compounds (antiperspirant agents) that are different from the zinc salts is preferred. Carboxylic acids are organic compounds that bear one or more carboxyl groups (-COOH). 15 The carboxylic acid salts are called carboxylates, and their esters are called carboxylic acid esters. The one or more zinc salts from the group of the salts of acetic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, and/or citric acid are selected as zinc salts of carboxylic acids according to the invention. 20 Zinc citrate is exceptionally preferred. Antiperspirants or deodorants are used to eliminate body odor that is produced when the fresh sweat, which in itself is odorless, is decomposed by microorganisms. The common cosmetic deodorants are based on different modes of action. In general usage, there is not always a clear distinction between the terms "deodorant" and 25 "antiperspirant." Instead, particularly in the German-speaking region, all products for use in the armpit region are referred to as deodorants or "Deos." This occurs regardless of whether there is also an antiperspirant action. Antiperspirants are sweat-preventing agents which - in contrast to deodorants, which generally prevent microbial decomposition of already formed sweat - should prevent sweat 30 from being excreted at all. The desired minimization of the sweat secretion can be achieved by means of various mechanisms. Traditionally, one of these mechanisms is the use of astringents, which cause protein precipitations and coagulations and thus effect a constriction or closure of the sweat gland.

4 New types of antiperspirant active ingredients are based, for example, on the principle of the anticholinergics, which interrupt the nerve impulses that lead to an increase in the secretion of the sweat glands. A further principle of new types of antiperspirant active ingredients is based on the 5 influencing of membrane transport processes in the cell. Specific aquaporin inhibitors inhibit the proteins that form channels in the cell membrane in order to make the passage of water and other molecules easier. Ion channel inhibitors have an effect on membrane transport processes and osmosis processes. A further new type of antiperspirant mode of action can be realized by using short-chain, vicinal diols; this mode of action possibly can be traced 10 back to the osmotic activity of said diols. According to the invention, if the use of an agent has no effect on the secretion of sweat, i.e., no antiperspirant effect is realized, an antiperspirant is not present. Thus, according to the invention, such substances that have an influence on the secretion of sweat are comprised as antiperspirant active ingredients. 15 In contrast to antiperspirants, pure deodorants have no active effect on the secretion of sweat, but rather merely control or affect the body odor or armpit odor (odor-improving agents). Common modes of action for this purpose are antimicrobial and antibacterial effects, which are also exhibited by, for example, non-colloidal silver, odor neutralization (masking), the 20 influencing of bacterial metabolisms, pure perfuming, and the use of precursors of certain perfume components, which are reacted by means of enzymatic reaction to form fragrant substances. Preparations can contain substances that inhibit the microbial decomposition of the sweat, such as triclosan, in addition to the actual antiperspirant active ingredients. Triclosan acts 25 against gram-positive and gram-negative microbes and against fungi and yeasts, and thus a deodorizing action but not an antiperspirant action results, because no effect on the secretion of sweat can be derived from the effect on the bacterial skin flora. Particularly for antiperspirants based on aluminum salts, the further addition of purely deodorizing substances can be dispensed with in principle, because said antiperspirants 30 have an antimicrobial potential per se. Furthermore, bacterial growth is inhibited by the reduced water supply due to the reduced secretion of sweat. The effectiveness improvement according to the invention due to the combination with selected zinc compounds remains unaffected by this. Within the meaning of the present application, antiperspirant active ingredients are to be 35 selected in particular from the following groups.

5 Astringents in particular, principally aluminum compounds, are used as antiperspirant active ingredients. The strongly acidic salts aluminum sulfate and aluminum chloride used earlier and agaric acid have largely been replaced by aluminum hydroxychloride and aluminum alcoholates. The following list of antiperspirant active ingredients to be used advantageously 5 should in no way be restrictive: Aluminum salts: . Aluminum salts such as aluminum chloride AlC13, aluminum sulfate A12(SO4)3 . Aluminum chlorides of the empirical formula [A12(OH)mCln], wherein m + n = 6 . Aluminum chlorohydrate [A12(OH)5CI] x H20 10 - Standard Al complexes: Locron P (Clariant), Micro-Dry (Reheis), ACH-331 (Summit), Aloxicoll PF 40 (Giulini). o Activated Al complexes: Reach 501 (Reheis), AACH-324 (Summit), AACH-7171 (Summit), Aloxicoll P (Giulini), Aloxicoll SD100 . Aluminum sesquichlorohydrate [Al2(OH)4.5C11.5] x H20 15 o Standard Al complexes: Aluminum sesquichlorohydrate (Reheis), AACH-308 (Summit) o Activated Al complexes: Reach 301 (Reheis) . Aluminum dichlorohydrate [A12(OH)4Cl2] x H20 Aluminum/zirconium salts: 20 Aluminum zirconium trichlorohydrex glycine [A14Zr(OH)13C3] x H20 x Gly o Standard AI/Zr complexes: Rezal 33GP (Reheis), AZG-7164 (Summit), Zirkonal P3G (Giulini) o Activated AI/Zr complexes: Reach AZZ 902 (Reheis), AAZG-7160 (Summit), Zirkonal AP3G (Giulini) 25 Aluminum zirconium tetrachlorohydrex glycine [A14Zr(OH)12C4] x H20 x Gly o Standard AI/Zr complexes: Rezal 36G (Reheis), AZG-368 (Summit), Zirkonal L435G (Giulini) o Activated AI/Zr complexes: Reach 908 (Reheis), AAZG-7167 (Summit), Zirkonal AP4G (Giulini) 30 . Aluminum zirconium pentachlorohydrex glycine [A18Zr(OH)23Cl5] x H20 x Gly . Aluminum zirconium octachlorohydrex glycine [A18Zr(OH)20C18] x H20 x Gly 6 However, glycine-free aluminum/zirconium salts can also be advantageous. Aluminum salts can be used not only as powder but also in dissolved "aqueous" form. The antiperspirant active ingredients from the groups mentioned above are used in the formulations according to the invention preferably in an amount of 1 to 30 wt%, with respect 5 to the total mass of the preparation, i.e., including any propellant gases present. If, for example, approx. 33.3 wt% of ACH (aluminum chlorohydrate, 50% aq.) is used in the active-ingredient solution for an aerosol spray (without propellant gas) and a filling ratio of approximately 30:70 (active-ingredient solution to propellant gas) is used, a content of approximately 5 wt% ACH is present in the final product. 10 "Active-ingredient solution" refers to the sum of all constituents except the propellant gas. Antiperspirant agents from the group of the anticholinergics, such as 4-[(2-cyclopentyl-2 hydroxyphenylacetyl)oxy]-1,1 -dimethyl-piperidinium salts, particularly 4-[(2-cyclopentyl-2 hydroxyphenylacetyl)oxy]-1,1 -dimethyl-piperidinium bromide, can be added at a proportion of preferably 0.05 to 1.0 wt%, more preferably 0.1 to 0.7 wt%, in particular 0.3 to 0.5 wt%, with 15 respect to the total mass of the preparation. Vicinal diols and similar active ingredients from the group of the osmotically active substances also can be added to the preparations according to the invention as antiperspirant active ingredients. Of course, it is possible to add further or other antiperspirant active ingredients and/or 20 deodorants as a cosmetically effective constituent. It was found that the combination of antimicrobial and/or antiperspirant agents with zinc salts of carboxylic acids leads to a synergistic effect with regard to improved deodorizing effect and improved protection against body odor. This finding is surprising and unforeseeable for a person skilled in the art. 25 The synergistic improvement of the deodorizing effect appeared in examinations of the die off kinetics of test microbes that are responsible for body odor. Figure 1 shows the die-off kinetics of the test microbe Staphylococcus epidermidis in an in vitro test design (suspension test). In the tests, the reduction in the cell count (CFU) of the test microbe was determined over time after treatment with aqueous solutions of aluminum 30 chlorohydrate (ACH), zinc citrate, and combinations thereof in a suitable concentration. As expected, ACH alone causes a large reduction of the test microbe that begins quickly. In contrast, zinc citrate alone exhibited only very poor effectiveness against the test microbe. In particular, an immediate effect (data points after 20 and 60 minutes) could hardly be detected. However, the combination of ACH with zinc citrate surprisingly resulted in a 7 significant improvement in the die-off kinetics over the short and medium terms. This effectiveness improvement is not simply the result of the addition of the individual effectiveness of the two substances, but rather is disproportionate and thus synergistic, as Figure 1 shows. 5 Table 1 shows the test microbe count after 20 minutes Cell count [CFU] Sample t1 (20 minutes), median ACH 429.62 ACH + zinc citrate 103.50 The suspension test on which the tests are based is known to a person skilled in the art as a standard method of the DGHM (1 September 2001). Zinc citrate is known as a constituent of dental care products because of the antiplaque 10 effect, which is based on the antibacterial effectiveness. Because conventional antiperspirant agents often already have very good antimicrobial effectiveness, it was astonishing that zinc carboxylates according to the invention and in particular zinc citrate enable a further effectiveness improvement of antiperspirant-containing deodorizing products. The one or more zinc salts are advantageously used at a proportion of 0.005 to 5 wt%, in 15 particular 0.01 to 0.5 wt%, with respect to the total mass of the preparation. A certain weight ratio of antiperspirant agent to zinc salt in the range of 4000:1 to 2:1 showed itself to be advantageous with regard to the effectiveness improvement. For example, a combination of 0.3 wt% of ACH and 0.1 wt% of zinc citrate, i.e., a preferred weight ratio of 3:1, showed itself to be advantageous in suspension tests. 20 In an antiperspirant spray that is advantageous according to the invention, a weight ratio of 35 wt% of ACH to 0.1 wt% of zinc citrate, i.e., a ratio of 350:1, showed itself to be especially advantageous with regard to the described effectiveness improvements. In a roll-on product, a ratio of 10 wt% of ACH to 0.01 wt% of zinc citrate, i.e., 1000:1, showed itself to be especially advantageous with regard to the described effectiveness improvements. 25 According to the invention, the addition of active ingredients for inhibiting carrier proteins and/or inhibitors of the expression of the androgen receptor, as described in the prior art, can be dispensed with. In particular, no resveratrol, epigallocatechin-3-gallate, flufenamic acid, monensin, tunicamycin, amphomycin, diumycin, showdomycin, tsushimycin, amphotericin, 8 mycospocidin, streptovirudin, and/or D-glucosamine is contained in the preparations according to the invention. The invention further relates to the use of one or more zinc salts of carboxylic acids in combination with one or more antimicrobial and/or antiperspirant compounds in cosmetic or 5 dermatological preparations in order to increase the deodorizing effect of said preparations after topical application. The deodorizing effect comprises, in particular, the protection against bad odor. This protection can be achieved according to the invention by means of an increased reduction of bacteria or the growth thereof. 10 In addition to the described improvements in the antimicrobial effectiveness that was presented in the in vitro test for the time period up to 3 hours, it was also possible to demonstrate very good in vivo long-term effectiveness (>24 h, in particular 48 h) against body odor for the products according to the invention. Accordingly, the zinc salts of the carboxylic acids can be used in combination with one or 15 more antimicrobial and/or antiperspirant compounds in cosmetic or dermatological preparations in order to reduce or prevent body odor for up to 48 hours after topical application of the preparation. The one or more zinc salts of the carboxylic acids are selected from the group of the salts of acetic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, and/or citric acid, in 20 particular zinc citrate. The cosmetic or dermatological preparations according to the invention can also contain cosmetic auxiliary agents and active ingredients, which are typically used in such preparations, such as active ingredients, preservatives, preservation aids, bactericides, substances for preventing foaming, dyes and pigments, thickeners, moistening and moisture 25 holding substances, or other common constituents of a cosmetic or dermatological formulation such as polyols, polymers, foam stabilizers, organic solvents, or silicone derivatives, provided that the addition is not ruled out and the required properties regarding antiperspirant and deodorizing effectiveness, stability, and skin-friendliness are not impaired. The preparations can be formulated as a spray, roll-on, stick, or gel. Emulsion preparations 30 according to the invention are preferably water-in-oil emulsions. Microemulsions are advantageously ruled out. The following examples illustrate preparations according to the invention. The numerical specifications are proportions by weight with respect to the total mass of the preparation. Examples 9 Antiperspirant suspension spray 1 2 3 4 % (w/w) % (w/w) % (w/w) % (w/w) Octyldodecanol 0.80 1.00 0.90 0.8 Tocopheryl Acetate 0.06 0.08 0.07 0.1 Dimethicone 2.34 3.20 3.10 3.0 Persea Gratissima Oil 0.10 0.15 0.10 0.5 Disteardimonium Hectorite 4.00 3.80 3.90 3.5 Propylene Carbonate 0.00 0.00 0.00 0.9 Isopropyl Palmitate 0.00 0.00 0.00 10.0 Cyclomethicone + Dimethiconol 0.00 0.00 0.00 2.3 Cyclomethicone 49.00 51.47 48.50 32.89 Aluminum Sesquichlorohydrate 0.00 2.00 0.00 5.0 Aluminum Chlorohydrate 35.00 33.00 37.00 35 Zinc Citrate 0.70 0.30 0.10 0.01 Perfume 5.33 5.00 5.10 6.0 Sodium Starch Octenylsuccinate + 2.67 0.00 1.23 0.00 Mannitol With propellant gas preferably butane/isobutane/propane and filling ratio of 5:95 to 30:70, preferably 10:90 to 20:80, preferably 15:85. Antiperspirant W/O spray 5 6 7 INCI % (w/w) % (w/w) % (w/w) % (w/w) 10 Aqua 47.5 47.0 45.25 Cyclomethicone 11.75 11.75 11.75 Aluminum Chlorohydrate (50% aq.) 20 20 20 Aluminum Sesquichlorohydrate (50% aq.) 0.00 0.00 2.0 C12-15 Alkyl Benzoate 5 5 5 Octyldodecanol 5 5 5 30 Dicaprylyl Ether 4 4 4 Perfume 3.3 3.3 3.3 Cetyl PEG/PPG-10/1 Dimethicone 1 1.5 1.5 Sorbitan Trioleate 1.5 1.5 1.5 Phenoxyethanol 0.5 0.5 0.5 Butyloctanoic Acid 0.25 0.25 0.00 Zinc Citrate 0.1 0.1 0.1 Persea Gratissima Oil 0.1 0.1 0.1 Butane, Isobutane, Propane 70 Antiperspirant sticks 8 9 10 11 % (w/w) % (w/w) % (w/w) % (w/w) Octyldodecanol 0.10 0.15 0.10 0.10 11 Glyceryl Stearate SE 0.60 0.60 0.65 1.00 Persea Gratissima Oil 0.05 0.07 0.05 0.10 Hydrogenated Castor Oil 1.50 1.50 1.60 1.50 Talc 4.00 2.50 3.65 2.00 PPG-14 Butyl Ether 15.00 14.43 0.00 20.00 Caprylic/Capric Triglyceride 0.00 0.00 14.50 10.00 Paraffinum Liquidum 0.00 0.00 0.00 7.50 Cyclomethicone 41.25 38.10 37.94 15.70 Aluminum Chlorohydrate 0.00 20.00 0.00 0.00 Aluminum Sesquichlorohydrate 0.00 0.00 0.00 1.00 Aluminum Zirconium Tetrachlorohydrex 16.00 0.00 20.00 19.00 GLY Stearyl Alcohol 20.00 21.1 20.50 21.00 Perfume 1.00 0.9 1.00 1.00 Zinc Citrate 0.50 0.65 0.01 0.10 Antiperspirant roll-on 12 13 14 15 % (w/w) % (w/w) % (w/w) % (w/w) Aqua 60.3 63.85 70.89 32.10 Alcohol 0.00 0.00 0.00 30.00 Aluminum Chlorohydrate (50% aq.) 28.00 17.50 20.00 28.00 PPG-1 5 Stearyl Ether 3.00 0.00 3.00 0.00 12 Octyldodecanol 0.00 3.00 0.00 0.25 Steareth-2 2.50 0.00 2.50 0.00 Glyceryl Isostearate 0.00 2.00 0.00 0.00 PEG-40 Hydrogenated Castor Oil 0.00 0.00 0.00 2.00 Dicaprylyl Carbonate 0.00 3.00 0.00 0.00 Aluminum Sesquichlorohydrate (50% aq.) 2.00 2.50 0.00 2.00 Trisodium EDTA (20% aq.) 1.50 0.00 1.50 0.00 Hydroxyethylcellulose 0.00 0.00 0.00 0.35 PEG-150 Distearate 0.00 0.80 0.00 0.00 Isosteareth-20 0.00 4.00 0.00 0.00 Steareth-21 1.50 0.00 1.00 0.00 Perfume 1.00 1.10 1.00 1.00 PEG-8 0.00 0.00 0.00 3.00 Glycerin 0.00 2.10 0.00 1.00 Persea Gratissima Oil 0.10 0.10 0.10 0.00 Zinc Citrate 0.10 0.05 0.01 0.30

Claims

1. Cosmetic or dermatological preparation comprising one or more zinc salts of carboxylic acids and one or more antimicrobial and/or antiperspirant compounds that are different 5 from the zinc salts, characterized in that the one or more zinc salts are selected from the group of the salts of acetic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, and/or citric acid.

2. Preparation according to claim 1, characterized in that zinc citrate is selected as a zinc salt. 10

3. Preparation according to one of the preceding claims, characterized in that aluminum salts, in particular aluminum chlorohydrates, are selected as antiperspirant compounds.

4. Preparation according to one of the preceding claims, characterized in that the proportion by weight of zinc salts is selected in the range of 0.001 to 5 wt%, in particular 0.01 to 0.5 wt%, with respect to the total mass of the preparation. 15

5. Preparation according to one of the preceding claims, characterized in that the proportion by weight of antimicrobial and/or antiperspirant compounds is selected in the range of 1 to 30 wt%, with respect to the total mass of the preparation.

6. Preparation according to one of the preceding claims, characterized in that the weight ratio of antimicrobial and/or antiperspirant compounds to zinc salts is selected in the range of 20 4000:1 to 2:1.

7. Preparation according to one of the preceding claims, characterized in that no active ingredients for inhibiting carrier proteins and/or inhibitors of the expression of the androgen receptor are contained in the preparations, in particular no resveratrol, epigallocatechin-3-gallate, flufenamic acid, monensin, tunicamycin, amphomycin, 25 diumycin, showdomycin, tsushimycin, amphotericin, mycospocidin, streptovirudin, and/or D-glucosamine.

8. Preparation according to one of the preceding claims, characterized in that the preparation is not a microemulsion.

9. Use of zinc salts of the carboxylic acids in combination with one or more antimicrobial 30 and/or antiperspirant compounds in cosmetic or dermatological preparations in order to increase the deodorizing effect of said preparations after topical application.

10. Use of zinc salts of the carboxylic acids in combination with one or more antimicrobial and/or antiperspirant compounds in cosmetic or dermatological preparations in order to reduce or prevent body odor for up to 48 hours after topical application of the preparation. 14

11. Use according to claim 8 or 9, characterized in that the one or more zinc salts are selected from the group of the salts of acetic acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, and/or citric acid.

12. Use according to claim 9, 10, or 11, characterized in that zinc citrate is selected as a zinc 5 salt.